In what has been a trying year for biotechnology stocks and exchange-traded funds, traders and investors are likely tired of hearing about when this group is finally going to deliver some legitimate upside.
Although the popular triple-leveraged biotech ETF Direxion Daily S&P Biotech Bull 3X Shares (NYSE: LABU) lost 3.5 percent Thursday, its month-to-date gain is still over 10 percent. That is good enough to make LABU one of Direxion's best-performing leveraged bullish ETFs to this point in May.
LABU Stands Out
Previously beloved biotech ETFs have been beaten up this year. Benchmark funds, such as the SPDR S&P Biotech (ETF) (NYSE: XBI), the ETF LABU is the triple-leveraged answer to, lost more than 20 percent in the first quarter. ...
/www.benzinga.com/general/biotech/16/05/8040241/this-biotech-etf-could-be-ready-to-party alt=This Biotech ETF Could Be Ready To Party>Full story available on Benzinga.com
More...